Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Biotechnology

Healthcare
$27.61 -1.93%

-$0.51 today

Market cap
$3.49B
Beta
1.52
P/E (TTM)
-1400.0
EPS (TTM)
-$0.02
52W Low $13.06High $31.77

Volume 0.84M

Average 1.61M

ARQT Long-term Debt

Borrowings due after more than one year.

Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Long-term Debt · Q2 FY2026 · quarter ended Jun 2026

Long-term debt falls 4.8% from a year ago

Long-term debt stood at $101.95M at the end of Q2 FY2026, down 4.8% from a year earlier and up 0.5% from the prior quarter. Over 3 fiscal years it compounded at -70.1% a year.

Context

  • Long-term debt amounted to 20.9% of total assets at the end of Q2 FY2026, down 9.5 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -4.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$101.95M+0.5% QoQ
Last fiscal yearDec 2025
$5.27M-95.1% YoY
Year agoJun 2025
$107.05M-4.8% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.8%——
1 year-95.1%——
3-year CAGR-70.1%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
5.27M USD
Year-over-year change
-95.1%
4-year CAGR
-48.1%

Long-term Debt vs competitors

How ARQT compares with its peers on the latest reported figures

  • ARQT's Jun 2026 long-term debt of $101.95M is the highest of the 6 companies compared; the peer median is $0.
  • Its year-over-year change of -4.8% is the highest of 3, against a peer median of -100.0%.
  • Long-term debt amounts to 20.9% of total assets for ARQT, versus a peer median of 0.0%.
ARQT Competitors Peer median
Long-term Debt for ARQT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ARQTArcutis Biotherapeutics, Inc.Jun 2026$101.95M -4.8%-70.1%20.9%
TTRXTurn Therapeutics Inc.Mar 2026$5.94M ——31.8%
ACRSAclaris Therapeutics, Inc.Mar 2026$0 ——0.0%
EVMNEvommune, Inc.Mar 2026$0 -100.0%—0.0%
SLGLSol-Gel Technologies Ltd.Mar 2026$0 ——0.0%
ALDXAldeyra Therapeutics, Inc.Mar 2026$0 -100.0%—0.0%
Peer median (excluding ARQT) $0-100.0%—0.0%

Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents97.99M53.64M88.4M71.34M42.91M
Short-term Investments290.61M355.95M183.46M156.62M178.08M
Net Receivables362K8.46M25.81M73.07M146.23M
Inventory07.51M13.13M14.53M22.63M
Other Current Assets7.66M4.46M9.53M8.82M9.79M
Total Current Assets402.77M437.41M330.43M335.82M411.23M
Property, Plant & Equipment (Net)5.3M4.6M3.9M2.99M5.51M
Goodwill00000
Intangible Assets07.19M6.44M9.48M14.81M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets78K78K596K596K1.42M
Total Non-current Assets5.38M11.87M10.93M13.07M21.74M
Total Assets408.15M449.27M341.37M348.89M432.97M
Account Payables7.35M8.83M11.99M14.22M12.53M
Short-term Debt433K0001M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities16.41M14.32M19.07M20.75M116.31M
Total Current Liabilities33.33M37.81M46.67M81.01M129.84M
Long-term Debt72.35M197.77M201.8M107.2M5.27M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities25K0849K570K108.39M
Total Non-current Liabilities77.15M201.89M206.03M110.34M113.66M
Total Liabilities110.48M239.69M252.7M191.35M243.49M
Common Stock5K6K9K12K12K
Retained Earnings(408.31M)(719.76M)(981.9M)(1.12B)(1.14B)
Accumulated OCI(255K)(1.09M)4K(7K)(44K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity297.68M209.58M88.67M157.54M189.48M
Total Debt77.56M202.54M205.92M110.59M6.27M
Net Debt(20.43M)148.9M117.52M39.25M(36.64M)

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Intrinsic Alpha fair value

Locked

Current Price

$27.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.